Stockscreener 앱 받기
60.25
1.42%
-0.94
전일 마감가:
$61.19
열려 있는:
$60.6
하루 거래량:
445.61K
Relative Volume:
0.32
시가총액:
$7.56B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
19.95
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-0.41%
1개월 성능:
+0.92%
6개월 성능:
+2.72%
1년 성능:
+51.14%
1일 변동 폭
$60.18
$61.15
1주일 범위
$59.53
$62.08
52주 변동 폭
$40.19
$66.00
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
60.34 | 7.56B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.97 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.04 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.19 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.08 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Halozyme reports annual meeting results, directors elected - Investing.com Australia
Halozyme reports annual meeting results, directors elected By Investing.com - Investing.com Nigeria
Director Krishnan Mahesh was granted 4,165 shares, increasing direct ownership by 64% to 10,666 units (SEC Form 4) - Quantisnow
Halozyme Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders - Quantisnow
Press Release Distribution & PR Platform - ACCESS Newswire
Halozyme Therapeutics: Still Undervalued Ahead Of Earnings (NASDAQ:HALO) - Seeking Alpha
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Alnylam (ALNY) and Halozyme (HALO) Secure EMA Panel Endorsements - GuruFocus
Halozyme to Report First Quarter 2025 Financial and Operating Re - GuruFocus
Halozyme (HALO) Gains EMA's Endorsement for VYVGART in CIDP Trea - GuruFocus
Director Henderson Jeffrey William sold $271,467 worth of shares (4,497 units at $60.37), decreasing direct ownership by 14% to 28,611 units (SEC Form 4) - Quantisnow
Alnylam, Halozyme among latest firms to win EU backing for drugs (HALO:NASDAQ) - Seeking Alpha
Halozyme Therapeutics Says VYVGART to Treat Rare Autoimmune Disease Receives CHMP Recommendation - marketscreener.com
Halozyme’s CIDP drug nears EU approval after CHMP nod - Investing.com
Halozyme to Report First Quarter 2025 Financial and Operating Results - marketscreener.com
Halozyme Announces argenx Received Positive CHMP Opinion for VYV - GuruFocus
Halozyme Announces Argenx Received Positive CHMP Opinion For Vyvgart (Efgartigimod Alfa) Subcutaneous Injection With Enhanze For CIDP - marketscreener.com
Breakthrough CIDP Treatment Advances: EU Panel Backs First New Therapy Option in Three Decades - Stock Titan
Halozyme shares surge 53% following InvestingPro’s November fair value call By Investing.com - Investing.com UK
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief - MSN
H.C. Wainwright maintains Buy on Halozyme stock, $72 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Halozyme stock, $72 target - Investing.com Australia
Halozyme sues Merck; FDA blames cuts for Vanda delay - BioPharma Dive
Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings) - Benzinga
Halozyme files lawsuit against Merck over SC Keytruda - The Pharma Letter
Halozyme sues Merck over alleged patent infringement By Investing.com - Investing.com South Africa
Halozyme sues Merck, alleging injectable Keytruda will infringe its patents - Endpoints News
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief By Stocktwits - Investing.com India
Merck Faces Lawsuit to Block Launch of Easier-to-Use Keytruda - Bloomberg.com
Halozyme Therapeutics (HALO) Files Lawsuit Against Merck Over Patent Infringement - GuruFocus
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Merck stock flat despite Halozyme patent suit (MRK:NYSE) - Seeking Alpha
Halozyme Files Patent Infringement Lawsuit Against Merck - Nasdaq
Halozyme sues Merck over alleged patent infringement - Investing.com
Halozyme (HALO) Sues Merck Over Keytruda's Subcutaneous Patent Infringement | HALO Stock News - GuruFocus
Halozyme Therapeutics Sues Merck Over Alleged Patent Infringement - marketscreener.com
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation | HALO Stock News - GuruFocus
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation - marketscreener.com
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet - simplywall.st
If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity - Yahoo
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market - MSN
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Pre - GuruFocus
Peering Into Halozyme Therapeutics's Recent Short Interest - Benzinga
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Henderson Jeffrey William | Director |
Apr 01 '25 |
Sale |
64.05 |
503 |
32,217 |
33,108 |
| Henderson Jeffrey William | Director |
Mar 03 '25 |
Sale |
58.69 |
5,000 |
293,458 |
33,611 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Feb 26 '25 |
Sale |
58.12 |
10,000 |
581,244 |
175,453 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Feb 25 '25 |
Sale |
58.05 |
10,000 |
580,534 |
185,453 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Feb 27 '25 |
Sale |
58.28 |
1,697 |
98,902 |
173,756 |
0.35%
0.36%
자본화:
|
볼륨(24시간):